Aclaris Therapeutics, Inc
Price
FilingsNewest: 13G, Stake over 5%, passiveSep 21 →InsidersNo open-market buys. 1 insider sold $1.4M in 1 sale, with no 10b5-1 plan named.→HoldersRa 9.1%BML 8.6%BlackRock 7.2%→Financing →PeersClosest companies: IMNM, KYMR, VOR→
From the filings
Figures
- Revenue
- $8.2Mlast 12 months
- Net income
- −$75.7Mlast 12 months
- Operating cash flow
- −$52.2Mlast 12 months
- Cash and equivalents
- $19.2Mat the last balance sheet
- Shares outstanding
- 139.8M shareson issue